Nasdaq · Healthcare

Syndax Pharmaceuticals Inc (SNDX)

As-reported financials and recent SEC filings for Syndax Pharmaceuticals Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$172.4M

Net income

$-285.4M

Net margin

—

Diluted EPS

$-3.29

ROE

-441.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$172.4M	$23.7M	$0	$0	$139.7M
Gross profit	—	—	—	—	—
Operating income	$-273.1M	$-339.7M	$-230.0M	$-151.8M	$26.2M
Net income	$-285.4M	$-318.8M	$-209.4M	$-149.3M	$24.9M
Diluted EPS	$-3.29	$-3.72	$-2.98	$-2.46	$0.46

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-06-12

42026-06-12

1442026-06-11

8-K2026-06-10

8-K2026-06-10

DEFA14A2026-06-04

8-K2026-06-04

42026-06-02

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on SNDX

Search Syndax Pharmaceuticals Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.